Latest Articles
- Updates in the medical management of Parkinson disease
Most, if not all, currently available drugs for Parkinson disease address dopaminergic loss and relieve symptoms. However, their adverse effects can be limiting and they do not address disease progression. Moreover, nonmotor features of Parkinson disease such as depression, dementia, and psychosis are now recognized as important and disabling. A cure remains elusive. However, promising interventions and agents are emerging. As an example, people who exercise regularly are less likely to develop Parkinson disease, and if they develop it, they tend to have slower progression.
- Is niacin ineffective? Or did AIM-HIGH miss its target?
The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) found, in an interim analysis, no cardiovascular benefit from taking extended-release niacin (Niaspan). In fact, there was a trend toward a greater risk of ischemic stroke, which did not reach statistical significance. But questions remain about this complex trial, which included intensive statin therapy in the active-treatment group and the control group.
- Heart failure in frail, older patients: We can do ‘MORE’
A comprehensive approach is necessary in managing heart failure in frail older adults. Physicians need to draw from the fields of internal medicine, geriatrics, and cardiology.
- Quality, frailty, and common sense
Ideal management of the frail elder with severe congestive heart failure is not always a matter of devices and drugs.